Related Experiment Video
Updated: Aug 22, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Health status of young children during therapy for advanced neuroblastoma
P C Nathan1, W Furlong, S De Pauw
1Department of Pediatrics, The Hospital for Sick Children, The University of Toronto, Toronto, Ontario, Canada.
Insights
Young children with advanced neuroblastoma experience significant health issues during treatment. Morbidity, particularly pain and emotional distress, peaks after diagnosis and bone marrow transplant.
Area of Science:
- Pediatric Oncology
- Child Health Status
- Neuroblastoma Treatment
Background:
- Advanced neuroblastoma significantly impacts young children's lives.
- Understanding treatment-related health status is crucial for supportive care.
Purpose of the Study:
- To describe the health status of young children undergoing advanced neuroblastoma therapy.
- To identify specific health domains most affected during treatment phases.
Main Methods:
- Study included 19 children (2-4.99 years) diagnosed with stage 3 or 4 neuroblastoma.
- Parents provided proxy assessments using the Comprehensive Health Status Classification System for Pre-school Children (CHSCS-PS).
- Assessments covered 10 health domains at up to 10 time points during therapy.
Main Results:
- 86 assessment questionnaires were completed.
- Maximum morbidity occurred immediately post-diagnosis and 2-3 weeks after bone marrow transplantation.
- Pain, self-care, mobility, and emotion domains showed the greatest morbidity.
Conclusions:
- Young children with advanced neuroblastoma face high mortality and considerable morbidity.
- Targeted interventions are needed to address pain, self-care, mobility, and emotional well-being during treatment.
Background:
The purpose of this study was to describe the health status experienced by young children during various phases of therapy for advanced neuroblastoma.
Methods:
Nineteen patients aged 2.00-4.99 years at the time of diagnosis of neuroblastoma (stages 3 or 4) who received active therapy between 1996 and 2000 were enrolled on the study. Their parents provided proxy assessments of their health status at a maximum of 10 assessment points during therapy using the Comprehensive Health Status Classification System for Pre-school Children (CHSCS-PS), which assesses level of function on 10 separate health domains.
Results:
Eighty-six assessment questionnaires were completed. Maximum morbidity was reported immediately following diagnosis and in the 2-3 weeks following bone marrow transplantation. The greatest morbidity was observed in the pain, self-care, mobility, and emotion domains.
Conclusions:
In addition to facing a high risk of mortality, young children being treated for advanced neuroblastoma also experience considerable morbidity.